AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28167545 — intervention group
Group type: EXPERIMENTAL
Intervention: MRX-I 800 mg every 12 hours for 28 days
Number of subjects: 66
Study 28167545 — intervention group
Group type: COMPARATOR
Intervention: Linezolid 600 mg every 12 hours for 28 days
Number of subjects: 66
Study 25294016 — intervention group
Group type: EXPERIMENTAL
Intervention: Siltuximab (6 mg/kg IV every 2 weeks) + Bortezomib (B)
Number of subjects: 281
Study 25294016 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Bortezomib (B)
Number of subjects: 281
Study 25294016 — intervention group
Group type: EXPERIMENTAL
Intervention: Siltuximab + Bortezomib
Number of subjects: 281
Study 25294016 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Bortezomib
Number of subjects: 281
Study 23590362 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia group
Number of subjects: 38
Study 23590362 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study 21255957 — intervention group
Group type: EXPERIMENTAL
Intervention: RVX-208 (50, 100, or 150 mg twice daily for 12 weeks)
Number of subjects: 299
Study 19593886 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled analgesia with lornoxicam (8 mg preoperatively, 8 mg after 6-8 hours, and 8 mg every 8 hours for 48 hours postoperatively)
Number of subjects: 126
Study 19593886 — intervention group
Group type: COMPARATOR
Intervention: On request analgesia with lornoxicam (as needed)
Number of subjects: 126
Study 19593886 — intervention group
Group type: EXPERIMENTAL
Intervention: Infratentorial craniotomy patients in group 1
Number of subjects: 126
Study 19593886 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean blood pressure
Number of subjects: 126
Study 19593886 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate
Number of subjects: 126
Study 16512935 — intervention group
Group type: COMPARATOR
Intervention: 0 g F&V per day (Control)
Number of subjects: 62
Study 16512935 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 g F&V per day
Number of subjects: 62
Study 16512935 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 g F&V per day
Number of subjects: 62
Study 15296886 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucodepletion using an arterial line leucocyte-depleting filter
Number of subjects: 50
Study 15296886 — intervention group
Group type: COMPARATOR
Intervention: Standard filter (Control)
Number of subjects: 50
Study 11385269 — intervention group
Group type: EXPERIMENTAL
Intervention: rizatriptan 10-mg rapidly disintegrating tablet
Number of subjects: 481
Study 11385269 — intervention group
Group type: EXPERIMENTAL
Intervention: rizatriptan 10-mg
Number of subjects: 481
Study 11385269 — intervention group
Group type: COMPARATOR
Intervention: sumatriptan 50-mg tablet
Number of subjects: 481
Study 9285433 — intervention group
Group type: EXPERIMENTAL
Intervention: Resective surgery
Number of subjects: 24
Study 8418302 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (1200 mg daily)
Number of subjects: 21
Study 8418302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 2874783 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine added to betaxolol treatment
Number of subjects: 19
Study 2874783 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine added to timolol treatment
Number of subjects: 19
Study 29853453 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ), an IL-6 receptor-α inhibitor, administered for 24 weeks.
Number of subjects: 12
Study 29853453 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered for 24 weeks.
Number of subjects: 12
Study 26711799 — intervention group
Group type: EXPERIMENTAL
Intervention: High-rate cutoff with VT therapy ≥200 (Treatment arm B)
Number of subjects: 1500
Study 26711799 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged 60-second delay for VT therapy ≥170 (Treatment arm C)
Number of subjects: 1500
Study 26711799 — intervention group
Group type: COMPARATOR
Intervention: Conventional with VT therapy ≥170 (Treatment arm A)
Number of subjects: 1500
Study 26711799 — intervention group
Group type: EXPERIMENTAL
Intervention: Any ICD programming
Number of subjects: 1500
Study 25330017 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine taper
Number of subjects: 113
Study 25330017 — intervention group
Group type: COMPARATOR
Intervention: Ongoing buprenorphine maintenance therapy
Number of subjects: 113
Study 23735180 — intervention group
Group type: EXPERIMENTAL
Intervention: Test sirolimus tablets
Number of subjects: 24
Study 23735180 — intervention group
Group type: COMPARATOR
Intervention: Reference sirolimus tablets
Number of subjects: 24
Study 20619475 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 microg PEG‐IFNalpha‐2a weekly with RBV 1000‐1200 mg/day for 12 weeks followed by 36 weeks of 180 microg PEG‐IFNalpha‐2a weekly plus RBV 1000‐1200 mg/day
Number of subjects: 896
Study 20619475 — intervention group
Group type: COMPARATOR
Intervention: 180 microg PEG‐IFNalpha‐2a weekly with RBV 1000‐1200 mg/day for 12 weeks followed by 36 weeks of 180 microg PEG‐IFNalpha‐2a weekly plus RBV 1000‐1200 mg/day
Number of subjects: 896
Study 18226255 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-based intervention supporting self-management of OA symptoms
Number of subjects: 104
Study 18226255 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 104
Study 15679790 — intervention group
Group type: EXPERIMENTAL
Intervention: Safyre sling procedure
Number of subjects: 126
Study 12817361 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 680
Study 10876066 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation (TM-Sidhi or yoga)
Number of subjects: 0
Study 10876066 — intervention group
Group type: COMPARATOR
Intervention: Control night (no meditation)
Number of subjects: 0
Study 8852414 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral B subunit‐killed whole cell (BS‐WC) vaccine
Number of subjects: 62285
Study 8852414 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed whole cell‐only (WC) vaccine
Number of subjects: 62285
Study 8852414 — intervention group
Group type: COMPARATOR
Intervention: K12 group (control)
Number of subjects: 62285
Study 1737542 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal insulin infusion (IP)
Number of subjects: 21
Study 1737542 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous intensive insulin therapy (SC)
Number of subjects: 21
Study 6151483 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 3837
Study 6151483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3837
Study 31575423 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure control targeting <120 mm Hg
Number of subjects: 8151
Study 31575423 — intervention group
Group type: COMPARATOR
Intervention: Systolic blood pressure control targeting 135 to 139 mm Hg
Number of subjects: 8151
Study 31575423 — intervention group
Group type: EXPERIMENTAL
Intervention: <10% 10‐year risk
Number of subjects: 8151
Study 31575423 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥30% 10‐year risk
Number of subjects: 8151
Study 31575423 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary prevention (≥30% risk)
Number of subjects: 8151
Study 31575423 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary prevention (≥30% risk)
Number of subjects: 8151
Study 29045659 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab + chemotherapy (BEV)
Number of subjects: 102
Study 29045659 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (CT)
Number of subjects: 102
Study 26914135 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg pregabalin per os (Group P75)
Number of subjects: 80
Study 26914135 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg pregabalin per os (Group P150)
Number of subjects: 80
Study 26914135 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg pregabalin per os (Group P300)
Number of subjects: 80
Study 26914135 — intervention group
Group type: COMPARATOR
Intervention: Control Group (Group C)
Number of subjects: 80
Study 24552826 — intervention group
Group type: EXPERIMENTAL
Intervention: Anabolic steroids combined with a daily high-protein, high-calorie diet
Number of subjects: 32
Study 24552826 — intervention group
Group type: COMPARATOR
Intervention: Control group (high-protein, high-calorie diet alone)
Number of subjects: 32
Study 22142813 — intervention group
Group type: EXPERIMENTAL
Intervention: Griffonia Simplicifolia extract (5-hydroxytryptophan) administered via oral spray for 4 weeks
Number of subjects: 20
Study 22142813 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered for 4 weeks
Number of subjects: 20
Study 19281581 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg tramadol
Number of subjects: 160
Study 19281581 — intervention group
Group type: COMPARATOR
Intervention: 50 mg pethidine
Number of subjects: 160
Study 17192712 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 45
Study 17192712 — intervention group
Group type: COMPARATOR
Intervention: Non-demented elderly control sample (n = 183)
Number of subjects: 45
Study 15776183 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (16 mg orally, administered 60 to 30 minutes before anesthesia)
Number of subjects: 178
Study 15776183 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered 60 to 30 minutes before anesthesia)
Number of subjects: 178
Study 12194123 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 25
Study 12194123 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy
Number of subjects: 25
Study 10581593 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined protocol (oral acipimox + insulin clamp)
Number of subjects: 20
Study 10581593 — intervention group
Group type: COMPARATOR
Intervention: Insulin clamp alone (control)
Number of subjects: 20
Study 10581593 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol (insulin clamp)
Number of subjects: 20
Study 8074597 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate disodium, 60 mg, over 4 hours
Number of subjects: 69
Study 8074597 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate disodium, 60 mg, over 24 hours
Number of subjects: 69
Study 8074597 — intervention group
Group type: COMPARATOR
Intervention: Saline alone
Number of subjects: 69
Study 2912119 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Number of subjects: 60
Study 2912119 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbachol
Number of subjects: 60
Study 2912119 — intervention group
Group type: COMPARATOR
Intervention: 0.5% balanced salt solution (placebo)
Number of subjects: 60
Study 31613029 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity blood flow restricted (BFR) training
Number of subjects: 24
Study 31613029 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIT)
Number of subjects: 24
Study 31613029 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity interval training without BFR (LOW)
Number of subjects: 24
Study 28583396 — intervention group
Group type: EXPERIMENTAL
Intervention: CompEx (composite outcome based on diary events and severe exacerbations)
Number of subjects: 12
Study 28583396 — intervention group
Group type: COMPARATOR
Intervention: Severe exacerbations
Number of subjects: 12
Study 26522337 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedaplatin plus docetaxel (100 mg/m² nedaplatin and 60 mg/m² docetaxel every 3 weeks for four to six cycles)
Number of subjects: 355
Study 26522337 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus docetaxel (80 mg/m² cisplatin and 60 mg/m² docetaxel every 3 weeks for four to six cycles)
Number of subjects: 355
Study 26522337 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Number of subjects: 355
Study 26522337 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin
Number of subjects: 355
Study 23413998 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine co-administration with clopidogrel
Number of subjects: 8
Study 22091692 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal comprehensive discharge‐planning intervention
Number of subjects: 665
Study 22091692 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 665
Study 19589442 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus‐eluting stents (EES)
Number of subjects: 649
Study 19589442 — intervention group
Group type: COMPARATOR
Intervention: Bare‐metal stents (BMS)
Number of subjects: 649
Study 19589442 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus‐eluting stents (SES)
Number of subjects: 649
Study 19589442 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel‐eluting stents (PES)
Number of subjects: 649
Study 16675081 — intervention group
Group type: EXPERIMENTAL
Intervention: Decline eccentric squats
Number of subjects: 13
Study 16675081 — intervention group
Group type: COMPARATOR
Intervention: Standard eccentric squats
Number of subjects: 13
Study 15182397 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenolic-rich dessert (200 g daily for 2 weeks)
Number of subjects: 22
Study 11986104 — intervention group
Group type: EXPERIMENTAL
Intervention: Artisan lens implantation
Number of subjects: 90
Study 11986104 — intervention group
Group type: COMPARATOR
Intervention: LASIK
Number of subjects: 90
Study 9848833 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthetic (one drop before lens insertion at fitting and dispensing visits)
Number of subjects: 80
Study 9848833 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthetic
Number of subjects: 80
Study 9848833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 8123500 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilutamide
Number of subjects: 24
Study 8123500 — intervention group
Group type: COMPARATOR
Intervention: D‐tryptophan‐6‐LHRH (Control)
Number of subjects: 24
Study 2812837 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (n = 11)
Number of subjects: 43
Study 2812837 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline (n = 18)
Number of subjects: 43
Study 2812837 — intervention group
Group type: COMPARATOR
Intervention: Historical control subjects (n = 21)
Number of subjects: 43
Study 2812837 — intervention group
Group type: COMPARATOR
Intervention: Patients with psychogenic pain with affective symptoms (n = 62)
Number of subjects: 43
Study 1120837 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral counseling group with hierarchically organized role playing and correctional feedback exercises
Number of subjects: 84
Study 1120837 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling plus group desensitization
Number of subjects: 84
Study 1120837 — intervention group
Group type: EXPERIMENTAL
Intervention: Microlab emphasizing structured real life interactions with females
Number of subjects: 84
Study 1120837 — intervention group
Group type: COMPARATOR
Intervention: Placebo procedure designed to increase personal awareness of nondating factors
Number of subjects: 84
Study 1120837 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 84
Study 31233373 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression therapy using a sports bra of compression type for 9 months
Number of subjects: 56
Study 31233373 — intervention group
Group type: COMPARATOR
Intervention: Standard bra for 9 months (Control)
Number of subjects: 56
Study 28837504 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 mg/d
Number of subjects: 7036
Study 28837504 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 40 mg/d
Number of subjects: 7036
Study 28837504 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/d
Number of subjects: 7036
Study 28837504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7036
Study 25319385 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 997
Study 25319385 — intervention group
Group type: COMPARATOR
Intervention: Crystalloids
Number of subjects: 997
Study 25319385 — intervention group
Group type: EXPERIMENTAL
Intervention: Presepsin concentration
Number of subjects: 997
Study 25319385 — intervention group
Group type: EXPERIMENTAL
Intervention: Presepsin concentration changes from day 1 to day 2
Number of subjects: 997
Study 25319385 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate antibiotic therapy
Number of subjects: 997
Study 25319385 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate antibiotic therapy
Number of subjects: 997
Study 25319385 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative blood cultures
Number of subjects: 997
Study 25319385 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive blood cultures
Number of subjects: 997
Study 22407393 — intervention group
Group type: EXPERIMENTAL
Intervention: Pascal dynamic contour tonometry
Number of subjects: 97
Study 22407393 — intervention group
Group type: COMPARATOR
Intervention: Goldmann applanation tonometry
Number of subjects: 97
Study 22407393 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both methods
Number of subjects: 97
Study 21323394 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (100-200 mg/day)
Number of subjects: 123
Study 19165196 — intervention group
Group type: EXPERIMENTAL
Intervention: Xelox+cetuximab
Number of subjects: 804
Study 19165196 — intervention group
Group type: COMPARATOR
Intervention: Xelox
Number of subjects: 804
Study 19165196 — intervention group
Group type: EXPERIMENTAL
Intervention: OxMdG+cetuximab
Number of subjects: 804
Study 19165196 — intervention group
Group type: COMPARATOR
Intervention: OxMdG
Number of subjects: 804
Study 17465457 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography (EUS)
Number of subjects: 63
Study 17465457 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of EUS and MMP-9
Number of subjects: 63
Study 17465457 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum MMP-9 levels
Number of subjects: 63
Study 15163163 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy Scale‐General (FACT‐G)
Number of subjects: 968
Study 15163163 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow transplantation
Number of subjects: 968
Study 15163163 — intervention group
Group type: COMPARATOR
Intervention: Breast cancer survivors
Number of subjects: 968
Study 15163163 — intervention group
Group type: COMPARATOR
Intervention: Survivors of Hodgkin's disease
Number of subjects: 968
Study 11310450 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for secondary NHL
Number of subjects: 52
Study 11310450 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS) for all patients with secondary NHL
Number of subjects: 52
Study 11310450 — intervention group
Group type: EXPERIMENTAL
Intervention: Freedom from treatment failure (FFTF) for all patients with secondary NHL
Number of subjects: 52
Study 11310450 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS) for patients with diffuse large-cell lymphoma
Number of subjects: 52
Study 11310450 — intervention group
Group type: EXPERIMENTAL
Intervention: Freedom from treatment failure (FFTF) for patients with diffuse large-cell lymphoma
Number of subjects: 52
Study 9146102 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature and severity of the plaintiff's injury
Number of subjects: 0
Study 9146102 — intervention group
Group type: EXPERIMENTAL
Intervention: Injury severity
Number of subjects: 0
Study 9146102 — intervention group
Group type: EXPERIMENTAL
Intervention: Disability and mental suffering associated with injuries
Number of subjects: 0
Study 9146102 — intervention group
Group type: COMPARATOR
Intervention: Perceived fault
Number of subjects: 0
Study 8198080 — intervention group
Group type: EXPERIMENTAL
Intervention: FR‐3 appliance therapy
Number of subjects: 40
Study 8198080 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 31124042 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2.5 mg or 100,000 IU)
Number of subjects: 5110
Study 31124042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5110
Study 27259508 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 100
Study 27259508 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical therapy (CMT)
Number of subjects: 100
Study 25564317 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized protocol for early stages of Convulsive Status Epilepticus (CSE) management
Number of subjects: 55
Study 25564317 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific guidelines for Convulsive Refractory Status Epilepticus (CRSE) management
Number of subjects: 55
Study 25564317 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement of neurologists in management
Number of subjects: 55
Study 25564317 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to continuous EEG monitoring
Number of subjects: 55
Study 23415417 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially harmful supplement use
Number of subjects: 21169
Study 23415417 — intervention group
Group type: COMPARATOR
Intervention: No CKD
Number of subjects: 21169
Study 23415417 — intervention group
Group type: COMPARATOR
Intervention: At risk of CKD
Number of subjects: 21169
Study 23415417 — intervention group
Group type: COMPARATOR
Intervention: Stages 1/2 CKD
Number of subjects: 21169
Study 23415417 — intervention group
Group type: COMPARATOR
Intervention: Stages 3/4 CKD
Number of subjects: 21169
Study 20637899 — intervention group
Group type: EXPERIMENTAL
Intervention: Interruptive alerts
Number of subjects: 0
Study 20637899 — intervention group
Group type: COMPARATOR
Intervention: Control group (no alerts)
Number of subjects: 0
Study 18484428 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin 2.5 mg
Number of subjects: 0
Study 18484428 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin 5 mg
Number of subjects: 0
Study 18484428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16939998 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline treatment in obese participants
Number of subjects: 488
Study 16939998 — intervention group
Group type: COMPARATOR
Intervention: Theophylline treatment in non-obese participants
Number of subjects: 488
Study 14671905 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface low-level endobronchial narcosis by isoflurane with high epidural anesthesia by bupivakain and fentanyl
Number of subjects: 82